Tag Archives: U.S.

Exclusive: Top U.S. insurer to cover Amgen, Eli Lilly migraine drugs, exclude Teva

NEW YORK (Reuters) – A top U.S. pharmacy benefit manager (PBM) owned by UnitedHealth Group Inc has included new migraine drugs from Amgen Inc and Eli Lilly and Co as preferred treatments on its lists of covered drugs, according to an OptumRx client note viewed by Reuters. Teva Pharmaceutical Industries Ltd’s rival migraine headache preventer… Read More »

Exelixis Announces U.S. FDA Approval of Cabometyx (cabozantinib) Tablets for Previously Treated Hepatocellular Carcinoma

Print this page ALAMEDA, Calif.–(BUSINESS WIRE)–Jan. 14, 2019– Exelixis, Inc. (NASDAQ:EXEL) today announced that the U.S. Food and Drug Administration (FDA) approved Cabometyx (cabozantinib) tablets for patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib. HCC is the most common form of liver cancer and the fastest-rising cause of cancer-related death in… Read More »

Shorter waits for new patients at VA than in private sector, U.S. study finds

(Reuters Health) – In many cases, veterans get a first appointment at VA hospitals quicker than the general public gets first appointments with health care providers, government researchers report. The researchers, all from the VA, compared wait times there for new patients to those for new patients in the private sector as determined by an… Read More »